Become a Creator today!Start creating today - Share your story with the world!
Start for free
00:00:00
00:00:01
245. Bull, Bear & Beyond – Worldwide Healthcare Trust in 60 seconds image

245. Bull, Bear & Beyond – Worldwide Healthcare Trust in 60 seconds

S1 E245 · Bull, Bear & Beyond by Edison Group
Avatar
1 Plays3 seconds ago

Get the lowdown from Edison’s Arron Aatkar on Worldwide Healthcare Trust (WWH), which delivered a meaningful return to form in FY26. WWH is a specialist investment trust offering diversified exposure to global healthcare.

**************************************************************************************

About ‘Bull, Bear & Beyond’

Bull, Bear & Beyond': features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

About Edison:

Edison is a content-led IR business. We believe quality investment content should inform all investors, not just brokers. Our mission: engage and build bigger, better-informed investor audiences for our clients.

Edison covers 50+ investment trusts, read about them here: https://www.edisongroup.com/equities/investment-companies/

Recommended
Transcript

Introduction and Financial Recovery of Worldwide Healthcare Trust

00:00:00
Speaker
Edison's investment companies team recently published a review on Worldwide Healthcare Trust, ticker WWH, w h specialist investment trust offering diversified exposure to global healthcare. care

Biotechnology and M&A Strategies Boosting Returns

00:00:12
Speaker
After a difficult financial year 2025, the trust delivered a meaningful return to form in the financial year 2026, with NAV and share price total returns of 10% and 13.1% respectively, well ahead of the benchmark's 1.8% return.
00:00:29
Speaker
Performance

Impact of Eased US Policy on Healthcare Sector

00:00:30
Speaker
was supported by the manager's continued focus on innovation and growth, particularly through biotechnology and the Trust's proprietary biotech M&A basket, which returned 55.9% in sterling terms.
00:00:43
Speaker
The managers,

Future Prospects: Biotech Valuations and Pharma M&A

00:00:44
Speaker
based at healthcare specialist Orbimed, believe the sector backdrop has improved as US policy uncertainty has eased. Looking ahead, attractive biotech valuations, sustained innovation and large farmers' need to replenish pipelines could continue to support m and a activity and further opportunities for value creation.